Big Pharma's shameful secret creates comically large investment opportunity
Rare FDA Loophole ignites new weight loss drug profit window
Dear Reader,
Here's something Big Pharma doesn't want you to know.
Those miracle weight loss drugs that have been plastered all over the news for the last couple of years…
That have been proven to treat not only weight issues, but slash the risk of up to 10 different cancers…
Reduce heart attack and stroke risk by 20%...
Even help treat dementia, liver disease and depression…
The ones the FDA calls "a major advance for public health." Which could help up to 70% of Americans avoid a premature death.
Well, here's Big Pharma's shameful secret about these miracle cures…
As you may already know, Big Pharma charges American citizens up to $1,500 a month for these drugs — a price so high that most insurance companies don’t cover them.
Guess how much they cost to produce?
$500?... $300?... $100?
Not even close.
$5.
Yes, you read that right. Five. Dollars.
Researchers at Yale University recently published findings showing semaglutide, the active ingredient in Ozempic and Wegovy, can be produced for between 89 cents and $4.73 a month.
And Big Pharma is selling these same drugs for up to $1,500 a month — pricing millions of Americans out of the market.
But recently, all that has changed.
The FDA has stepped in…
It’s triggered a little-known loophole that’s effectively taken these drugs “off patent” for a short amount of time…
So right now, there are a series of small pharma disruptors producing and selling these same drugs for 85% less than Big Pharma — and still making huge profits.
Creating a once-in-a-lifetime profit window for investors…
And allowing the little guy to get one over on Big Pharma for once.
Which is why Citigroup describes the market opportunity from this rare situation as “comically large.”
As you can see in my urgent presentation, I predict it could hand regular investors a shot at as much as 4X their money in 12 months.
That’s enough to turn a modest stake of $5,000 into $20,000 by this time next year.
Go here now for the full story… before this loophole slams shut.
Regards,
Adam O'Dell
Chief Investment Strategist, Money & Markets